On Wednesday, Chief Executive of Edwards Lifesciences Corp., Michael Mussallem said that the revenue of the company is expected to grow beyond 10% by the year 2010. The Irvine-based company deals in making heart valves. At the Reuters Health Summit in New York, Mussallem told all the people present in the Summit that “We are tracking above the 10% rate … and would expect that to continue. I do not think Wall Street will be disappointed.”

Wall Street is backing this fully and this outlook presented by Edwards Lifesciences Corp. had topped Wall Street’s expectations. Analysts on Wall Street are expecting that the company will report revenue of approximately $1.42 billion in the coming year. This would mark an 8% hike in comparison with the current year as the revenue for the present year has been projected at $1.31 billion.

Earlier the company had announced that the revenue for the current year would come in at around $1.30 billion to $1.35 billion for the year 2009. Mussallem said that in the year 2010, the heart valves, heart surgery devices and critical-care products would be in great demand and this would increase the sales and help in generating higher revenue.

This entry was posted on Friday, November 13th, 2009 at 12:01 pm and is filed under Venture Capital Funding, Venture Capital News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.